Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Laroprovstat/Rosuvastatin in Lipid-Lowering Treatment-Naïve Patients with Hypercholesterolaemia
NCT07619131Phase 3Recruiting
- Sponsor
- AstraZeneca
- Start
- Aug 2026
- Primary completion
- Jul 2027
- Countries
- 11
01
Overview
Phase 3, randomised, double-blind trial of laroprovstat in hypercholesterolemia (6 arms), sponsored by AstraZeneca. Primary endpoint: Relative change in Low-Density Lipoprotein Cholesterol at 8 weeks. Started Aug 2026; status: recruiting.
02
Drugs
laroprovstat
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT07619131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07619131.